This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Acorda Therapeutics Management

Management criteria checks 3/4

Acorda Therapeutics' CEO is Ron Cohen, appointed in Jan 1995, has a tenure of 28.67 years. total yearly compensation is $984.15K, comprised of 63.5% salary and 36.5% bonuses, including company stock and options. directly owns 0.6% of the company’s shares, worth €85.15K. The average tenure of the management team and the board of directors is 5.6 years and 25.7 years respectively.

Key information

Ron Cohen

Chief executive officer

US$984.2k

Total compensation

CEO salary percentage	63.5%
CEO tenure	28.7yrs
CEO ownership	0.6%
Management average tenure	5.6yrs
Board average tenure	25.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ron Cohen's remuneration changed compared to Acorda Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2023	n/a	n/a	-US$21m
Mar 31 2023	n/a	n/a	-US$58m
Dec 31 2022	US$984k	US$625k	-US$66m
Sep 30 2022	n/a	n/a	-US$106m
Jun 30 2022	n/a	n/a	-US$119m
Mar 31 2022	n/a	n/a	-US$95m
Dec 31 2021	US$2m	US$743k	-US$104m
Sep 30 2021	n/a	n/a	-US$166m
Jun 30 2021	n/a	n/a	-US$132m
Mar 31 2021	n/a	n/a	-US$127m
Dec 31 2020	US$2m	US$796k	-US$100m
Sep 30 2020	n/a	n/a	US$49m
Jun 30 2020	n/a	n/a	-US$222m
Mar 31 2020	n/a	n/a	-US$232m
Dec 31 2019	US$2m	US$796k	-US$273m
Sep 30 2019	n/a	n/a	-US$329m
Jun 30 2019	n/a	n/a	-US$79m
Mar 31 2019	n/a	n/a	-US$6m
Dec 31 2018	US$2m	US$796k	US$34m
Sep 30 2018	n/a	n/a	-US$147m
Jun 30 2018	n/a	n/a	-US$158m
Mar 31 2018	n/a	n/a	-US$213m
Dec 31 2017	US$2m	US$792k	-US$223m
Sep 30 2017	n/a	n/a	-US$55m
Jun 30 2017	n/a	n/a	-US$43m
Mar 31 2017	n/a	n/a	-US$53m
Dec 31 2016	US$3m	US$773k	-US$35m

Compensation vs Market: Ron's total compensation ($USD984.15K) is above average for companies of similar size in the German market ($USD418.12K).

Compensation vs Earnings: Ron's compensation has been consistent with company performance over the past year.

CEO

Ron Cohen (67 yo)

28.7yrs

Tenure

US$984,150

Compensation

Dr. Ron Cohen, M.D., has been the Founder of Acorda Therapeutics, Inc. since 1995 and has been its Chief Executive Officer and President since 1995. Dr. Cohen served as Principal in the startup of Advanced...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Ron Cohen	Founder	28.7yrs	US$984.15k	0.60% € 85.2k
Michael Gesser	Chief Financial Officer	1.8yrs	US$459.15k	0% € 0
Kerry Clem	Chief Commercial Officer	2yrs	US$592.23k	0.041% € 5.7k
Robert Morales	Interim Principal Accounting Officer	2.5yrs	no data	no data
Felicia Vonella	Vice President of Investor Relations	no data	no data	no data
Neil Belloff	General Counsel & Corporate Secretary	1.8yrs	no data	0% € 0
Tierney Saccavino	Executive Vice President of Corporate Communications	8.7yrs	no data	no data
Denise Duca	Executive Vice President of Human Resources	8.7yrs	no data	no data
Andrew Mayer	Senior Vice President	no data	no data	no data
Sofia Ali	Senior VP of Operations & Strategic Planning	no data	no data	no data
Susan Way	Senior VP of Drug Development & Regulatory Affairs	no data	no data	no data
Wise Young	Special Scientific Advisor	no data	US$10.00k	no data

5.6yrs

Average Tenure

61.5yo

Average Age

Experienced Management: CDG's management team is seasoned and experienced (5.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Ron Cohen	Founder	28.7yrs	US$984.15k	0.60% € 85.2k
Carl Cotman	Member of Scientific Advisory Board	no data	no data	no data
Sandra Panem	Independent Director	25.7yrs	US$72.64k	0.0019% € 272.6
Mark Tuszynski	Member of Scientific Advisory Board	no data	no data	no data
Melitta Schachner	Member of Scientific Advisory Board	no data	no data	no data
Patrick Tresco	Member of Scientific Advisory Board	no data	no data	no data
Stephen Waxman	Member of Scientific Advisory Board	no data	no data	no data
Mary Bunge	Member of Scientific Advisory Board	no data	no data	no data
James Fawcett	Member of Scientific Advisory Board	no data	no data	no data
Michael Beattie	Member of Scientific Advisory Board	no data	no data	no data
Jerry Silver	Member of Scientific Advisory Board	no data	no data	no data
John Kelley	Independent Non-Executive Chairman	14.8yrs	US$127.49k	0% € 0

25.7yrs

Average Tenure

72.5yo

Average Age

Experienced Board: CDG's board of directors are seasoned and experienced ( 25.7 years average tenure).

This company listing is no longer active

Acorda Therapeutics Management

Management criteria checks 3/4

Key information

Recent management updates

Insufficient new directors

Acorda Therapeutics Announces Resignation of Lauren Sabella as Chief Operating Officer

Insufficient new directors

Acorda Therapeutics, Inc. Announces Board Changes

Insufficient new directors

Acorda Therapeutics Announces Executive Changes

Recent updates

First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc.

Acorda Therapeutics Files Form 15

Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million.

Solicitation Version of First amended Disclosure Statement Approved for Acorda Therapeutics, Inc.

Nasdaq Files Form 25 with the U.S. Securities and Exchange Commission to Delist Acorda Therapeutics's Common Stock from Nasdaq, Effective on May 5, 2024

Acorda Therapeutics Announces Delisting from Nasdaq

Acorda Therapeutics, Inc.(OTCPK:ACOR.Q) dropped from NASDAQ Composite Index

Motion for Asset Sale Filed by Acorda Therapeutics, Inc.

Merz Pharmaceuticals, LLC entered into an asset purchase agreement to acquire Substantially all of the Companys assets of Acorda Therapeutics, Inc. for approximately $190 million.

Motion for Joint Administration Filed by Acorda Therapeutics, Inc.

Acorda Therapeutics, Inc. to Report Q4, 2023 Results on Apr 01, 2024

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023

Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA

Acorda Therapeutics, Inc. Reaffirms Revenue Guidance for the Full Year 2023

Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Acorda Therapeutics Announces Completion of Reverse Stock Split to Enable the Company to Regain Compliance with the Minimum Closing Price Required to Maintain Continued Listing on the Nasdaq Global Select Market

Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split to Regain Compliance with the Minimum Closing Price Required to Maintain Continued Listing

First quarter 2023 earnings released: US$0.69 loss per share (vs US$1.85 loss in 1Q 2022)

Acorda Therapeutics, Inc. Reaffirms Earnings Guidance for the Year 2023

Full year 2022 earnings released: US$3.35 loss per share (vs US$9.79 loss in FY 2021)

Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement

Acorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request A Hearing

Third quarter 2022 earnings released: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021)

Acorda Therapeutics, Inc. Provides Earnings Guidance for the Years of 2022, 2023, 2024, 2025, 2026 and 2027

Acorda Therapeutics, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Acorda Therapeutics Announces Resignation of Lauren Sabella as Chief Operating Officer

Second quarter 2022 earnings released: US$2.78 loss per share (vs US$2.29 loss in 2Q 2021)

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2022

Acorda Therapeutics Receives Deficiency Letter Listing Qualifications Department of Nasdaq Stock Market

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Year 2022

First quarter 2022 earnings released: US$1.93 loss per share (vs US$3.53 loss in 1Q 2021)

Insufficient new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Acorda Therapeutics, Inc. Announces Board Changes

Insufficient new directors

Third quarter 2021 earnings released: US$2.43 loss per share (vs US$0.92 profit in 3Q 2020)

Independent Director Barry Greene has left the company

Independent Director Catherine D. Strader has left the company

Second quarter 2021 earnings released: US$2.29 loss per share (vs US$2.19 loss in 2Q 2020)

First quarter 2021 earnings released: US$3.53 loss per share (vs US$0.81 loss in 1Q 2020)

Acorda Therapeutics, Inc. Provides Financial Guidance for the Full Year of 2021

Revenue beats expectations

Full year 2020 earnings released: US$12.32 loss per share (vs US$34.47 loss in FY 2019)

Acorda Therapeutics Announces Executive Changes

Catalent Pharma Solutions, Inc. completed the acquisition of INBRIJA Manufacturing Operations in Chelsea, Massachusetts from Acorda Therapeutics, Inc. (NasdaqGS:ACOR).

Acorda Therapeutics Announces Completion of Sale of Manufacturing Operations to Catalent

Acorda Therapeutics, Inc.(NasdaqGS:ACOR) dropped from Russell 2000 Dynamic Index

Catalent Pharma Solutions, Inc. entered into an asset purchase agreement to acquire INBRIJA Manufacturing Operations in Chelsea, Massachusetts from Acorda Therapeutics, Inc. (NasdaqGS:ACOR) for $80 million.

New 90-day high: €5.42

Third quarter 2020 earnings released: EPS US$0.15

Revenue beats expectations

New 90-day high: €0.89

Acorda Therapeutics, Inc. to Report Q3, 2020 Results on Nov 03, 2020

Steven M. Rauscher to Resign as Member of Board of Directors of Acorda Therapeutics, Inc

Acorda Therapeutics, Inc.(NasdaqGS:ACOR) dropped from S&P Global BMI Index

New 90-day low - €0.40

New 90-day low - €0.50

First half earnings released

Acorda Therapeutics, Inc.(NasdaqGS:ACOR) dropped from Russell 2000 Value Index

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age